Vet Portal

No products in the cart.

About OncoBark
It's all in our name: OncoBark means to bark at cancer EARLY.

We have the determination to unravel the link between differential DNA energetics and tumorigenesis in an attempt to transform the cancer care on a global scale.  With more than 40 years of experiences on cutting-edge molecular technology, we pursue the truth engraved in our DNA “bond” for a better way cancer is diagnosed and monitored.

We act with humility

Our horizon is continuously expanding beyond qPCR to RACH, beyond cancer to aging, beyond animals to human, to address unmet clinical needs, always with the wellness of DNA in our mind.

We believe in you

We believe wholeheartedly in the power of people. OncoGx16 has the potential to play an important role in the fight to save pets’ lives and improve their outcomes. And you can help make it happen.

We strive to be the best

We are the first-in-class and best-in-class. Everything we do, we do it for the very best.

We make it affordable, accessible and accurate

WE make it simple and accurate, like a pregnancy test. Our goal is that OncoGx16 should be affordable, robust and available to all.

We dare to be unique

We seek to challenge the status quo for the well beings of animals and people alike. We dare to change the world by exploiting the energetic information hidden in DNA conformation to detect disease earlier, monitor it more effectively and improve its outcomes.

We aspire to excel

We aim high to get precision instantaneous DNA diagnostics in everyday life.

Because We are Scientists, Not Just Businessmen

We are scientists with over 30 years of passionate experience and devotion to precision DNA diagnostics. Our cutting-edge DNA technology can accurately determine the oncological conditions of your pet dogs with a smidge of exoDNA from the philtrum swab sample.


Pet Owner

Cancer lurks behind stress.  Don’t let stress sink under your pet’s skin. 


Triaging cancer patients is a matter of determining the severity of their in-depth conditions.

Vet Oncologist

Cancer is a genomic disease. Altered genomic stability accounts for the evolution of cancer development.


At-home early cancer detection for our pet dog is no trivial matter, but that is exactly what Dr. CN Wang and Dr. Bing Ling set out to do. Today, we are proud to unveil a fast, easy and affordable cancer DNA test for sophisticated pet owners in the world.  Our scientific and clinical training demands the highest standard and delivers the worlds’ first point-of-care cancer diagnostic test.  We will work with you to deter cancer and regain a longer, happier life for your pet.

The Company is formed on March 1990 at Boston by Dr. CN Wang (Princeton), Dr. Kai Wu (Cornell Medical) and Dr. Thomas Wang (Chicago U) based on the discovery of a proprietary resonance energy transfer mechanism across nucleic acid strands. 

Our Mission: To elucidate molecular differential energetics for precision cancer diagnosis.

Our Belief: To understand the behavior of DNA is to know yourself at molecular level.


Cancer is a systemic disease with evolving genomic instability, which is the driving force of tumor initiation and progression.  While the underlying mechanism of this force remains elusive, altered DNA sequence/confirmation of cancer genome inevitably attributes to the functional impairment of its activities.

As cancer genome evolves, its homeostatic stability degenerates, reflecting the progressive thermodynamic deformation of the genomic DNA configuration.  This hallmark account of carcinogenesis has eluded scientists in their quest for cancer “liquid biopsy” owing to the lack of quantitative means to predict the energetics of DNA conformation,

Using an advanced DNA technology, the canine OncoGuarDx test is the first of its kind to determine the cell free DNA’s energetic levels at either excessive or cancerous stress state.  As a point-of-care test, the canine OncoGuarDx exams the dynamic stability of the dog philtrum DNA and generates color-coded results in real time, revealing the actual stress level that our pet dog is currently enduring.   Unlike conventional diagnostic test, the OncoGuarDx is a probe-less assay, employing no biologically derived agents and pose no environmental concerns to the pet owner.


Meet the Team










Why Choose Our OncoGx16 Cancer Test?

The OncoGx16 exosome DNA biopsy test uses a simple nose swab to detect abnormal DNA of cancer exosomes, which enter nasal philtrum effusively from the circulating body fluid.

Incredibly Accurate

OncoGx16 uses state-of-the-art differential DNA energetic technology to detect changes in DNA that are indicative of specific types of cancer.  The overall sensitivity is greater than 98% and its specificity approaches 100%.

Extremely Simple

OncoGx16 requires only a simple nose swab. The entire OncoGx16 test is embodied in a lateral flow device similar to human pregnancy test, which can take place anytime, anywhere for any breed.

Absurdly Affordable

OncoGx16 adopts lateral flow assay into a proprietary cutting-edge technology to eliminate the high costs inexorably associated with Next-Gen DNA sequencing and conventional DNA amplification.

Multi-Cancer Early Detection

OncoGx16 can concomitantly detect 16 specific types of cancer, including 7 of the most common canine cancers before their clinical signs are noticeable.



“Early detection and treatment are the best ways to manage cancer in pets… cancer is frequently treatable and early diagnosis will aid your veterinarian in delivering the best care possible.”

— American Veterinary Medical Association

OncoGx16 & OncoGuarDx Can Help Safeguard Furry Kids from Cancers

What is cancer screening?

Cancer screening refers to exams or tests performed on someone who does not currently have any signs of cancer, but who does have a higher risk of cancer due to age and/or breed.

What are the benefits of early screening?

Early treatments are the best ways to manage cancer. Cancer is frequently treatable and early diagnosis will aid your veterinarian in delivering the best care possible.

What are the current guidelines for cancer screening?

Screening guidelines are well established in human medicine for various cancer types. Yet formal cancer screening guidelines have not yet been established in veterinary medicine. General health screening recommendations include annual or biannual exams and routine lab works which may detect some cancer types.

Which dogs have urgent need for cancer screening?

Dogs at higher risk of cancer or over age 7.  Certain breeds have a higher lifetime risk of cancer, and some breeds also have a higher risk of being diagnosed at an earlier age.  However, older dogs are at higher risk of cancer, regardless of breed.

What is OncoGx16?

OncoGx16 is a first-in-class test specifically developed to detect cancer at home.  The test only requires a simple nose philtrum swab sample and can take place anywhere, anytime for any breed without fasting or any restrictive conditions.

What types of cancer can OncoGx16 detect?

OncoGx16 is a multi-cancer early detection test meaning it detects multiple types of cancers. You can view a list here of cancer types specifically formulated for the OncoGx16 Test Kit.

What type of DNA is OncoGx16 testing? What is exosome DNA?

OncoGx16 is a philtrum swab-based exosome DNA biopsy test that focuses on exosome DNAs (exoDNA), which enter philtrum from circulating body fluid. OncoGx16 analyzes exoDNA in the sample to identify differential DNA energetic alterations in the DNA conformation that featured cancer-specific epigenetic alterations.

What are the benefits to using OncoGx16?

OncoGx16 empowers pet owners to provide first-response care to their furry kids by ruling out the possibility of the dreadful disease, when indifferentiable signs of illness are noticed. As a multi-cancer detection test, OncoGx16 detects a wide spectrum of cancers, including the 7 most common cancers. When used for screening, OncoGx16 may help pet parents detect cancer earlier, thereby improving the outcomes. When used as an aid in diagnosis, OncoGx16 can provide useful information for tumors that may be difficult to access by fine needle aspiration, biopsy or surgery due to accessibility in the body.